BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a report issued on Tuesday. The firm currently has a $93.98 price target on the stock. Vetr‘s price objective would suggest a potential upside of 9.75% from the company’s previous close.

BMRN has been the topic of several other reports. Jefferies Group raised their target price on BioMarin Pharmaceutical from $116.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Piper Jaffray Cos. raised their target price on BioMarin Pharmaceutical from $107.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Stifel Nicolaus raised their target price on BioMarin Pharmaceutical from $107.00 to $113.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Barclays PLC raised their target price on BioMarin Pharmaceutical from $105.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $111.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 8th. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $114.35.

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) opened at 85.63 on Tuesday. BioMarin Pharmaceutical has a 52-week low of $62.12 and a 52-week high of $107.56. The company’s market capitalization is $14.73 billion. The company has a 50 day moving average of $86.14 and a 200 day moving average of $89.66.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 27th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.13. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The company earned $279.90 million during the quarter, compared to the consensus estimate of $289.70 million. During the same period last year, the company earned ($0.60) EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 34.0% on a year-over-year basis. On average, equities research analysts forecast that BioMarin Pharmaceutical will post ($3.73) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Vetr Inc. Upgrades BioMarin Pharmaceutical Inc. (BMRN) to “Buy”” was published by Financial Market News and is owned by of Financial Market News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at http://www.financial-market-news.com/vetr-inc-upgrades-biomarin-pharmaceutical-inc-bmrn-to-buy/1211829/.

In related news, CEO Jean Jacques Bienaime sold 69,743 shares of the business’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $85.69, for a total transaction of $5,976,277.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Robert Ajer sold 18,467 shares of the business’s stock in a transaction on Tuesday, September 27th. The shares were sold at an average price of $95.61, for a total value of $1,765,629.87. Following the transaction, the executive vice president now owns 41,342 shares of the company’s stock, valued at approximately $3,952,708.62. The disclosure for this sale can be found here. Corporate insiders own 2.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of BMRN. Parametrica Management Ltd boosted its position in BioMarin Pharmaceutical by 149.4% in the second quarter. Parametrica Management Ltd now owns 6,507 shares of the company’s stock worth $506,000 after buying an additional 3,898 shares during the last quarter. LS Investment Advisors LLC boosted its position in BioMarin Pharmaceutical by 13.5% in the second quarter. LS Investment Advisors LLC now owns 1,946 shares of the company’s stock worth $151,000 after buying an additional 231 shares during the last quarter. IBM Retirement Fund boosted its position in BioMarin Pharmaceutical by 1.8% in the second quarter. IBM Retirement Fund now owns 19,233 shares of the company’s stock worth $1,562,000 after buying an additional 346 shares during the last quarter. Hartford Investment Management Co. boosted its position in BioMarin Pharmaceutical by 2.5% in the second quarter. Hartford Investment Management Co. now owns 2,906 shares of the company’s stock worth $226,000 after buying an additional 70 shares during the last quarter. Finally, Rockefeller Financial Services Inc. acquired a new position in BioMarin Pharmaceutical during the second quarter worth about $111,000. Institutional investors own 97.54% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.